Preoperative growth dynamics of untreated glioblastoma – Description of an exponential growth-type, correlating factors and association with postoperative survival

IF 3.7 Q1 CLINICAL NEUROLOGY Neuro-oncology advances Pub Date : 2024-04-03 DOI:10.1093/noajnl/vdae053
Daniel Feucht, P. Haas, M. Skardelly, F. Behling, D. Rieger, Paula Bombach, F. Paulsen, E. Hoffmann, Till-Karsten Hauser, Benjamin Bender, M. Renovanz, Maximilian Niyazi, Ghazaleh Tabatabai, M. Tatagiba, Constantin Roder
{"title":"Preoperative growth dynamics of untreated glioblastoma – Description of an exponential growth-type, correlating factors and association with postoperative survival","authors":"Daniel Feucht, P. Haas, M. Skardelly, F. Behling, D. Rieger, Paula Bombach, F. Paulsen, E. Hoffmann, Till-Karsten Hauser, Benjamin Bender, M. Renovanz, Maximilian Niyazi, Ghazaleh Tabatabai, M. Tatagiba, Constantin Roder","doi":"10.1093/noajnl/vdae053","DOIUrl":null,"url":null,"abstract":"\n \n \n Little is known about growth dynamics of untreated glioblastoma and its possible influence on postoperative survival. Our aim was to analyze a possible association of preoperative growth dynamics with postoperative survival.\n \n \n \n We performed a retrospective analysis of all adult patients surgically treated for newly diagnosed glioblastoma at our center between 2010 and 2020. By volumetric analysis of data of patients with availability of ≥3 preoperative sequential MRI, a growth pattern was aimed to be identified. Main inclusion criterion for further analysis was the availability of two preoperative MRI scans with a slice thickness of 1mm, at least 7 days apart. Individual growth rates were calculated. Association with overall survival (OS) was examined multivariably.\n \n \n \n Out of 749 patients screened, thirteen had ≥3 preoperative MRI, 70 had two MRI and met the inclusion criteria.\n A curve estimation regression model showed best fit for exponential tumor growth.\n Median tumor volume doubling time (VDT) was 31 days, median specific growth rate (SGR) was 2.2% growth per day. SGR showed negative correlation with tumor size (rho=-0.59, p<0.001). Growth rates were dichotomized according to the median SGR.OS was significantly longer in the group with slow growth (log rank: p=0.010). Slower preoperative growth was independently associated with longer overall survival in a multivariable Cox-regression model for patients after tumor resection.\n \n \n \n Especially small lesions suggestive for glioblastoma showed exponential tumor growth with variable growth rates and a median VDT of 31 days. SGR was significantly associated with OS in patients with tumor resection in our sample.\n","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology advances","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.1093/noajnl/vdae053","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Little is known about growth dynamics of untreated glioblastoma and its possible influence on postoperative survival. Our aim was to analyze a possible association of preoperative growth dynamics with postoperative survival. We performed a retrospective analysis of all adult patients surgically treated for newly diagnosed glioblastoma at our center between 2010 and 2020. By volumetric analysis of data of patients with availability of ≥3 preoperative sequential MRI, a growth pattern was aimed to be identified. Main inclusion criterion for further analysis was the availability of two preoperative MRI scans with a slice thickness of 1mm, at least 7 days apart. Individual growth rates were calculated. Association with overall survival (OS) was examined multivariably. Out of 749 patients screened, thirteen had ≥3 preoperative MRI, 70 had two MRI and met the inclusion criteria. A curve estimation regression model showed best fit for exponential tumor growth. Median tumor volume doubling time (VDT) was 31 days, median specific growth rate (SGR) was 2.2% growth per day. SGR showed negative correlation with tumor size (rho=-0.59, p<0.001). Growth rates were dichotomized according to the median SGR.OS was significantly longer in the group with slow growth (log rank: p=0.010). Slower preoperative growth was independently associated with longer overall survival in a multivariable Cox-regression model for patients after tumor resection. Especially small lesions suggestive for glioblastoma showed exponential tumor growth with variable growth rates and a median VDT of 31 days. SGR was significantly associated with OS in patients with tumor resection in our sample.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
未经治疗的胶质母细胞瘤的术前生长动力学--指数生长类型的描述、相关因素以及与术后存活率的关系
人们对未经治疗的胶质母细胞瘤的生长动态及其对术后生存的可能影响知之甚少。我们的目的是分析术前生长动态与术后生存可能存在的关联。 我们对 2010 年至 2020 年在本中心接受新诊断胶质母细胞瘤手术治疗的所有成人患者进行了回顾性分析。通过对术前≥3次连续核磁共振成像的患者数据进行容积分析,旨在确定生长模式。进一步分析的主要纳入标准是患者术前至少有两次相隔 7 天、切片厚度为 1 毫米的磁共振成像扫描。计算单个生长率。对总生存率(OS)进行了多变量分析。 在筛选出的 749 名患者中,13 人术前磁共振成像≥3 次,70 人有两次磁共振成像,符合纳入标准。曲线估计回归模型显示肿瘤指数增长的最佳拟合度。肿瘤体积倍增时间(VDT)中位数为31天,比生长率(SGR)中位数为每天增长2.2%。SGR 与肿瘤大小呈负相关(rho=-0.59,p<0.001)。生长速度根据中位 SGR 进行二分。生长速度慢的一组的 OS 明显更长(对数秩:P=0.010)。在肿瘤切除术后的多变量Cox回归模型中,术前生长速度较慢的患者总生存期较长。 特别是提示为胶质母细胞瘤的小病灶,肿瘤呈指数增长,增长率不一,中位VDT为31天。在我们的样本中,SGR与肿瘤切除患者的OS明显相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊最新文献
International symposium on inheritable central nervous system (CNS) cancer predisposition: A prologue. Correction to: Effect of bevacizumab on refractory meningiomas: 3D volumetric growth rate versus response assessment in neuro-oncology criteria. Effect of antibiotic drug use on outcome and therapy-related toxicity in patients with glioblastoma-A retrospective cohort study. Empowering the next generation in neuro-oncology: Introduction of the EANO Career Boost Initiative. A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1